The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Image-Guided Gynecologic Brachytherapy
- Conditions
- Cervical CancerVaginal CancerVulvar CancerBladder CancerUterine Cancer
- Interventions
- Device: Image-Guided Brachytherapy
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-07
- Target Recruit Count
- 54
- Registration Number
- NCT02993900
- Locations
- 🇺🇸
The SKCCC at Johns Hopkins, Baltimore, Maryland, United States
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
- Conditions
- Chordoma
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: NivolumabRadiation: Stereotactic Radiosurgery
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-06-06
- Target Recruit Count
- 21
- Registration Number
- NCT02989636
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2021-02-10
- Target Recruit Count
- 17
- Registration Number
- NCT02981524
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
- Conditions
- Metastatic Breast Cancer
- Interventions
- Other: Treatment recommendation
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-10-02
- Target Recruit Count
- 200
- Registration Number
- NCT02965755
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, United States
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2024-12-27
- Target Recruit Count
- 33
- Registration Number
- NCT02923180
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
- Conditions
- Solid Tumors Induced by Prior Radiation Exposure
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2019-08-28
- Target Recruit Count
- 6
- Registration Number
- NCT02864316
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center @ Johns Hopkins, Baltimore, Maryland, United States
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: 18F DCFPyL- Radiopharmaceutical
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2020-05-07
- Target Recruit Count
- 18
- Registration Number
- NCT02856100
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Urothelial CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2024-08-02
- Target Recruit Count
- 15
- Registration Number
- NCT02845323
- Locations
- 🇺🇸
UCLA Institute of Urologic Oncology, Los Angeles, California, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2023-03-09
- Target Recruit Count
- 67
- Registration Number
- NCT02845297
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
- Conditions
- Bone Marrow FailureAplastic AnemiaImmunosuppressionSevere Aplastic Anemia
- Interventions
- Radiation: Total body irradiation
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-07-12
- Target Recruit Count
- 21
- Registration Number
- NCT02833805
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States